SMARCA2 and acute myeloid leukemia: In AML tumors, these analyses showed that OOS caused the upregulation of CDC25A (fold change: 1.19, p-value: 0.026), PRTM5 (fold change: 1.17, p-value: 0.018), and SERPINE1 (fold change: 1.56, p-value: 0.042), and the downregulation of SMARCA2 (fold change: −1.38, p-value: 0.015), PTGDR2 (fold change: −1.53, p-value: 0.001), and DHFR (fold change: −1.18, p-value: 0.036) (Figure 3A,C).